Your Source for Venture Capital and Private Equity Financings

Venture Capital News: TwinStrand Biosciences Inks $50M Series B

2021-05-07
SEATTLE, WA, TwinStrand Biosciences has closed a $50 million Series B financing led by Section 32.
TwinStrand Biosciences has closed a $50 million Series B financing led by Section 32, with participation from new investors Soleus Capital, Janus Henderson Investors, and existing investors Madrona Venture Group, Ridgeback Capital, and Alexandria Venture Investments, among others.

TwinStrand's biochemistry and software-based solution enables researchers and clinicians to detect genetic 'needles in a haystack.' By identifying ultra-low frequency DNA mutations with a resolution 10,000-fold greater than conventional tools on the market, TwinStrand enables detection, quantification, and characterization of variants that were previously undetectable.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors